Publication | Closed Access

Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis

Metabolic SyndromeHepatologyCardiovascular DiseaseHealth SciencesMedicineLiver PhysiologyPathologyHyperlipidemiaPharmacotherapyLipoprotein MetabolismFatty Liver DiseasePooled AnalysisPharmacologyAtherosclerosisDyslipidemiaAtherogenic Dyslipidemia